SCHEMBL4706571

SCHEMBL4706571

CCOC(=O)C1CCN(c2nc(Cl)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
ALDH1A1 P00352 4/20 0.60
POLB P06746 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
CTSB P07858 1/20 0.57
HTT P42858 2/20 0.56
VCAM1 P19320 1/20 0.56
TP53 P04637 1/20 0.56
GPR119 Q8TDV5 6/20 0.52
KMT2A Q03164 4/20 0.50
MEN1 O00255 2/20 0.50
USP2 O75604 1/20 0.50
THRB P10828 1/20 0.50
S100A4 P26447 1/20 0.50
RECQL P46063 1/20 0.50
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10964799 0.84 MAPT (0.55) MAPTALDH1A1POLBTDP1L3MBTL1
SCHEMBL4255322 0.82 CTSB (0.68) MAPTALDH1A1CTSBHTTTP53
SCHEMBL389055 0.80 GPR119 (0.58) MAPTALDH1A1CTSBHTTVCAM1
SCHEMBL6529147 0.80 MAPT (0.68) MAPTALDH1A1POLBTDP1L3MBTL1
SCHEMBL389089 0.80 MAPT (0.61) MAPTALDH1A1CTSBHTTTP53
SCHEMBL389349 0.80 GPR119 (0.52) MAPTALDH1A1POLBL3MBTL1CTSB
SCHEMBL3538908 0.80 TDP1 (0.59) MAPTALDH1A1POLBTDP1L3MBTL1
SCHEMBL389221 0.79 GPR119 (0.51) MAPTALDH1A1POLBCTSBHTT
SCHEMBL388686 0.79 MAPT (0.50) MAPTALDH1A1POLBL3MBTL1CTSB
SCHEMBL390261 0.79 CTSB (0.50) MAPTALDH1A1POLBCTSBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606282-B1 PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM ARENA PHARM INC (US) 2008-11-12 EP disclosed
US-20070066590-A1 Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism ARENA PHARMACEUTICALS, INC. 2007-03-22 US disclosed
EP-1606282-A2 PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM Arena Pharmaceuticals, Inc. (US) 2005-12-21 EP disclosed
WO-2004076413-A2 PHENYL- AND PYRIDYLPIPERIDINE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM ARENA PHARMACEUTICALS, INC. (US) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066590-A1 Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism GPR119, PC, PLPBP MAPT 3871/4885ALDH1A1 260/4885POLB 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.